150 related articles for article (PubMed ID: 27479823)
1. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.
Muchtar E; Dispenzieri A; Kumar SK; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
Haematologica; 2016 Sep; 101(9):1102-9. PubMed ID: 27479823
[TBL] [Abstract][Full Text] [Related]
2. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Muchtar E; Magen H; Itchaki G; Cohen A; Rosenfeld R; Shochat T; Kornowski R; Iakobishvili Z; Raanani P
Leuk Res; 2016 Feb; 41():56-61. PubMed ID: 26658109
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
4. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.
Muchtar E; Dispenzieri A; Kumar SK; Buadi FK; Lacy MQ; Zeldenrust S; Hayman SR; Leung N; Kourelis TV; Gonsalves W; Chakraborty R; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Go R; Kyle RA; Rajkumar SV; Gertz MA
Leukemia; 2017 Jan; 31(1):92-99. PubMed ID: 27211265
[TBL] [Abstract][Full Text] [Related]
5. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
7. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Zeldenrust SR; Tan T; Sinha S; Leung N; Kyle RA; Rajkumar SV; Gertz MA
Am J Hematol; 2011 Mar; 86(3):251-5. PubMed ID: 21328431
[TBL] [Abstract][Full Text] [Related]
8. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N; Sidana S; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Fonder AL; Hobbs MA; Hayman SR; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Am J Hematol; 2017 Jun; 92(6):549-554. PubMed ID: 28314084
[TBL] [Abstract][Full Text] [Related]
11. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation.
Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W
Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
13. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
[TBL] [Abstract][Full Text] [Related]
14. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
15. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
16. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Dingli D; Buadi FK; Grogan M; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Dispenzieri A
Blood; 2017 Apr; 129(15):2111-2119. PubMed ID: 28126928
[TBL] [Abstract][Full Text] [Related]
18. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Yagüe J; Bladé J
Amyloid; 2017 Dec; 24(4):245-252. PubMed ID: 29052436
[TBL] [Abstract][Full Text] [Related]
20. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
